Yuhan Corporation

Janssen Biotech, Inc.

Su Bin Choi

Sol Park

Hyun Ho Choi

Dong Hoon Kim

Tae Dong Han

Eun Kyung Kim

Hee Jae Tak

Na Ry Ha

Mi Kyeong Ju

Tae Wang Kim

Scott D Kuduk

Jae Young Sim

Kwan Hoon Hyun

Hyunjoo Lee

Young Ae Yoon

Marian C Bryan

James Campbell Robertson

Eun Hye Jung

Misong Kim

So Young Kim

Byung-Chul Suh

Jaekyoo Lee

Paresh Salgaonkar

Gyu Jin Lee

Jong Sung Koh

So Young Hwang

Byoungmoon Lee

Tae Kyun Kim

Eui Chul Lee

Eui Chui Lee

Heejun Kim

Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors

Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors

Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

Substituted aminopyridine compounds as EGFR inhibitors

The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Growing community of inventors

Yongin-si, South Korea

Su Bin Choi